Immune Response Corp. and Rhone-Poulenc Rorer Inc. saidThursday that they each have agreed to invest an additional $9million in their AIDS joint venture, Immunization Products Ltd.

The companies are developing a therapeutic vaccine for HIV-infected patients. The vaccine, which uses a whole killed virusdepleted of the gp120 outer envelope, is in Phase II/III trials.

The $18 million will be used to support the ongoing trials, aswell as additional planned trials and expenses related to thepotential commercialization of the vaccine. The funds will beprovided in several installments this year and in 1993.

The new investment will bring to $36 million the totalinvestment in the joint venture. The companies said additionalfunds may be needed to support development of the vaccine.

Immune Response shares (NASDAQ:IMNR) lost 75 cents to$18.50.

(c) 1997 American Health Consultants. All rights reserved.